Clinical trials: Bipolar Disorder in Remission
Bipolar Disorder, Sub-syndromal Symptoms
Evaluation of Sub-syndromal Symptoms After Acute Depressive Episode in Bipolar Disorder
The study aims to evaluate: the frequency of subsyndromal symptoms or disorders observed during interepisode phases in bipolar patients, particularly after a depressive episode in which these subsyndromal disorders are the most…
- Trial name
- POLARIS (NCT01663974)
- Where
- 86 sites in France
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Bipolar Depression, Suicidal Ideation
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of…
- Trial name
- SBD-ASIB (NCT03396068)
- Testing
- NRX-101, Lurasidone HCl
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- NeuroRx, Inc.
Bipolar Disorder
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
This is a randomized, parallel, open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode, with or without psychotic symptoms, with olanzapine in mono or co-therapy, and who…
- Trial name
- NCT00191997
- Testing
- Olanzapine
- Where
- 11 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
The precursor study (SCA101469) was an open-label, prospective multicentre study in adult subjects diagnosed with bipolar disorder consisting of 36 weeks treatment with lamotrigine.
- Trial name
- NCT00360126
- Testing
- lamotrigine
- Where
- 3 sites in Australia
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline